报价延迟最少15分钟:2025/07/16 02:55 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
82.95 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-4.42/-3.50
|
|
企业价值
6.08B
|
| 资产负债 |
|
每股账面净值
14.08
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/16 02:55 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20. |
